Breaking News
Get 45% Off 0
👀 Ones to Watch: The MOST undervalued stocks to buy right now
See Undervalued Stocks

Zacks Investment Research Zacks Investment Research

Zacks Investment Research's Opinion & Analysis.
Featured here: a complete archive of all posts and research produced by Zacks Investment Research, including current material.
10 Inverse ETFs That Gained More Than 30% Over The Past Week By Zacks Investment Research - Feb 26, 2020

The rapidly spreading coronavirus has made investors jittery this week, sending the global market into a tailspin. Notably, the S&P 500 declined more than 7% from records set just a week ago. ...

ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales By Zacks Investment Research - Feb 26, 2020

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reported fourth-quarter 2019 loss of 34 cents per share, narrower than the Zacks Consensus Estimate of a loss of 37 cents as well as the year-ago loss of 50...

Nutanix's (NTNX) Earnings And Revenues Beat Estimates In Q2 By Zacks Investment Research - Feb 26, 2020

Nutanix (NASDAQ:NTNX) incurred second-quarter fiscal 2020 loss of 60 cents per share, beating the Zacks Consensus Estimate by 13%. However, the figure was wider than the year-ago loss of 23...

Discovery (DISCA) Q4 Earnings Beat Mark, Revenues Rise Y/Y By Zacks Investment Research - Feb 26, 2020

Discovery (NASDAQ:DISCA) reported fourth-quarter 2019 adjusted earnings of 98 cents per share, beating the Zacks Consensus Estimate by 5.4% and also increasing 19.5% year over year.Revenues...

ANSYS (ANSS) Q4 Earnings Beat Estimates, Revenues Rise Y/Y By Zacks Investment Research - Feb 26, 2020

ANSYS (NASDAQ:ANSS) reported fourth-quarter 2019 non-GAAP earnings of $2.24 per share, which beat the Zacks Consensus Estimate by 12.6% and also increased 5.2% year over year.Non-GAAP revenues of...

Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates By Zacks Investment Research - Feb 26, 2020

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) incurred an adjusted loss of $1.57 per share in the fourth quarter of 2019, wider than the year-ago adjusted loss of 85 cents per share. The wider...

Nielsen's (NLSN) Q4 Earnings Match Estimates, Revenues Beat By Zacks Investment Research - Feb 26, 2020

Nielsen Holdings plc (NYSE:NLSN) reported fourth-quarter 2019 adjusted net earnings of 41 cents per share, which matched the Zacks Consensus Estimate. Further, the bottom line was down 19.6% from...

United Therapeutics (UTHR) Down On Q4 Earnings & Sales Miss By Zacks Investment Research - Feb 26, 2020

United Therapeutics (NASDAQ:UTHR) reported earnings of $1.20 per share for the fourth quarter of 2019, down 18.9% year over year. The Zacks Consensus Estimate was pegged at $2.47The abovementioned...

Arena Pharmaceuticals (ARNA) Q4 Earnings Miss, Revenues Top By Zacks Investment Research - Feb 26, 2020

Arena Pharmaceuticals, Inc. ARNA incurred loss of $1.76 per share for the fourth quarter of 2019, wider than the Zacks Consensus Estimate of a loss of $1.62. The company had recorded earnings of $1.35...

BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox In Focus By Zacks Investment Research - Feb 26, 2020

BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) adjusted earnings of 25 cents per share beat the Zacks Consensus Estimate of 21 cents. In the year-ago quarter, the company had incurred loss of 6...

Lawson Products (LAWS) Surpasses Q4 Earnings Estimates By Zacks Investment Research - Feb 26, 2020

Lawson Products (LAWS) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.22 per share a year ago. These...

Continue with Apple
Continue with Google
or
Sign up with Email